Cargando…
Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular events in patients with heart failure irrespective of diabetes status. In this prespecified sub-analysis of randomised-controlled trial, we investigated the efficacy of luseogliflozin (2.5 mg daily), a sodium–glucose cotransporter...
Autores principales: | Ejiri, Kentaro, Miyoshi, Toru, Kihara, Hajime, Hata, Yoshiki, Nagano, Toshihiko, Takaishi, Atsushi, Toda, Hironobu, Namba, Seiji, Nakamura, Yoichi, Akagi, Satoshi, Sakuragi, Satoru, Minagawa, Taro, Kawai, Yusuke, Nishii, Nobuhiro, Fuke, Soichiro, Yoshikawa, Masaki, Nakamura, Kazufumi, Ito, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474821/ https://www.ncbi.nlm.nih.gov/pubmed/36104378 http://dx.doi.org/10.1038/s41598-022-19371-6 |
Ejemplares similares
-
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020) -
Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021) -
The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial
por: Ejiri, Kentaro, et al.
Publicado: (2019) -
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
por: Oe, Hiroki, et al.
Publicado: (2015) -
Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2017)